149 related articles for article (PubMed ID: 11556751)
1. Antigenic characterization of medullary carcinoma of the breast: HLA-DR expression in lymph node positive cases.
Lazzaro B; Anderson AE; Kajdacsy-Balla A; Hessner MJ
Appl Immunohistochem Mol Morphol; 2001 Sep; 9(3):234-41. PubMed ID: 11556751
[TBL] [Abstract][Full Text] [Related]
2. HLA-DR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities.
Feinmesser M; Sulkes A; Morgenstern S; Sulkes J; Stern S; Okon E
J Clin Pathol; 2000 Apr; 53(4):286-91. PubMed ID: 10823125
[TBL] [Abstract][Full Text] [Related]
3. The Immunophenotype of Nodular Variant of Medullary Carcinoma of the Breast.
Reyes C; Nadji M
Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):624-7. PubMed ID: 25710588
[TBL] [Abstract][Full Text] [Related]
4. Expression of MHC class I and class II antigens in primary breast carcinomas and synchronous nodal metastases.
Maiorana A; Cesinaro AM; Fano RA; Collina G
Clin Exp Metastasis; 1995 Jan; 13(1):43-8. PubMed ID: 7820955
[TBL] [Abstract][Full Text] [Related]
5. Gains and losses of HLA class II (DR) and CD4 in atypical hyperplasia, carcinoma in situ and infiltrating ductal carcinoma of the breast.
Tamiolakisl D; Venizelos I; Lambropoulou M; Jivannakis T; Seliniotakis E; Tsikouras P; Limberis V; Tsalkidis A; Papadopoulos N
Acta Medica (Hradec Kralove); 2004; 47(4):257-62. PubMed ID: 15844251
[TBL] [Abstract][Full Text] [Related]
6. HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx.
Esteban F; Ruiz-Cabello F; Concha A; Pérez-Ayala M; Sánchez-Rozas JA; Garrido F
Clin Exp Metastasis; 1990; 8(4):319-28. PubMed ID: 2350918
[TBL] [Abstract][Full Text] [Related]
7. Metaplastic and medullary mammary carcinomas do not express mammaglobin.
Reyes C; Gomez-Fernández C; Nadji M
Am J Clin Pathol; 2012 May; 137(5):747-52. PubMed ID: 22523213
[TBL] [Abstract][Full Text] [Related]
8. Antigenic phenotype of the lymphocytic component of medullary carcinoma of the breast.
Ben-Ezra J; Sheibani K
Cancer; 1987 Jun; 59(12):2037-41. PubMed ID: 3032398
[TBL] [Abstract][Full Text] [Related]
9. Expression of glycodelin in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastases.
Shabani N; Mylonas I; Kunert-Keil C; Briese V; Janni W; Gerber B; Friese K; Jeschke U
Anticancer Res; 2005; 25(3A):1761-4. PubMed ID: 16033096
[TBL] [Abstract][Full Text] [Related]
10. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.
Rosen PP; Lesser ML; Arroyo CD; Cranor M; Borgen P; Norton L
J Clin Oncol; 1995 Apr; 13(4):821-30. PubMed ID: 7707107
[TBL] [Abstract][Full Text] [Related]
11. The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators.
Georgiannos SN; Renaut A; Goode AW; Sheaff M
Surgery; 2003 Nov; 134(5):827-34. PubMed ID: 14639362
[TBL] [Abstract][Full Text] [Related]
12. Tumor infiltrating lymphocytes differ in invasive micropapillary carcinoma and medullary carcinoma of breast.
Guo X; Fan Y; Lang R; Gu F; Chen L; Cui L; Pringle GA; Zhang X; Fu L
Mod Pathol; 2008 Sep; 21(9):1101-7. PubMed ID: 18469794
[TBL] [Abstract][Full Text] [Related]
13. Expression of HLA-DR is reduced in tumor infiltrating immune cells (TIICs) and regional lymph nodes of non-small-cell lung carcinomas. A putative mechanism of tumor-induced immunosuppression?
Foukas PG; Tsilivakos V; Zacharatos P; Mariatos G; Moschos S; Syrianou A; Asimacopoulos PJ; Bramis J; Fotiadis C; Kittas C; Gorgoulis VG
Anticancer Res; 2001; 21(4A):2609-15. PubMed ID: 11724329
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of T-cell infiltrates, expression of beta 2-microglobulin and HLA-DR antigens in breast carcinoma.
Lucin K; Iternicka Z; Jonjić N
Pathol Res Pract; 1994 Dec; 190(12):1134-40. PubMed ID: 7792204
[TBL] [Abstract][Full Text] [Related]
15. Medullary breast carcinoma vs. poorly differentiated ductal carcinoma: an immunohistochemical study with keratin 19 and oestrogen receptor staining.
Jensen ML; Kiaer H; Melsen F
Histopathology; 1996 Sep; 29(3):241-5. PubMed ID: 8884352
[TBL] [Abstract][Full Text] [Related]
16. Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes.
Kotlan B; Simsa P; Teillaud JL; Fridman WH; Toth J; McKnight M; Glassy MC
J Immunol; 2005 Aug; 175(4):2278-85. PubMed ID: 16081796
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody-defined phenotypes of regional lymph node and peripheral blood lymphocyte subpopulations in early breast cancer.
Morton BA; Ramey WG; Paderon H; Miller RE
Cancer Res; 1986 Apr; 46(4 Pt 2):2121-6. PubMed ID: 3081262
[TBL] [Abstract][Full Text] [Related]
18. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall.
Recine MA; Deavers MT; Middleton LP; Silva EG; Malpica A
Am J Surg Pathol; 2004 Dec; 28(12):1646-51. PubMed ID: 15577686
[TBL] [Abstract][Full Text] [Related]
19. Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis.
Redondo M; García J; Villar E; Rodrigo I; Perea-Milla E; Serrano A; Morell M
Hum Pathol; 2003 Dec; 34(12):1283-9. PubMed ID: 14691914
[TBL] [Abstract][Full Text] [Related]
20. FAS and FAS-L expression by tumor cells and lymphocytes in breast carcinomas and their lymph node metastases.
Ioachim HL; Decuseara R; Giancotti F; Dorsett BH
Pathol Res Pract; 2005; 200(11-12):743-51. PubMed ID: 15792116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
